Focused On-demand Library for Gamma-glutamylaminecyclotransferase

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q9BVM4

UPID:

GGACT_HUMAN

Alternative names:

AIG2-like domain-containing protein 1; Gamma-glutamylamine cyclotransferase

Alternative UPACC:

Q9BVM4; B3KTN1; Q9BT41

Background:

Gamma-glutamylaminecyclotransferase, also known as AIG2-like domain-containing protein 1, plays a crucial role in protein degradation. It specifically targets proteins cross-linked by transglutaminases, breaking the bond between lysine and glutamic acid residues. This action facilitates the formation of 5-oxo-L-proline from L-gamma-glutamyl-L-epsilon-lysine, showcasing its unique enzymatic activity.

Therapeutic significance:

Understanding the role of Gamma-glutamylaminecyclotransferase could open doors to potential therapeutic strategies. Its specific enzymatic function in protein degradation pathways highlights its importance in cellular processes and disease mechanisms.